RAS Blockade in hypertension
RAS Blockade in the management of hypertension
Dr. Peter Meredith discusses structural differences in different drugs used for blood pressure management. This is done from a pharmacological viewpoint where he discusses the influence of insurmountability of a compound in relation to stability of attained therapeutic concentration. He discusses the role of combination therapy, and its value in refractory patients. He concludes with considerations in setting the proper target blood pressure in the treatment of hypertension.
Questions to be addressed in this PACE expert opinion are:
- Differences between ARB's: What are the key lessons from comparisons?
- What is the role of combination versus monotherapy in the management of hypertension?
- What is the 'ideal' blood pressure to achieve?
View the expert opinion interview with dr. Meredith
More about the speaker
Dr Peter Meredith
University of Glasgow, Department of Medicine and Therapeutics,
Gardiner Institute, Western Infirmary, Glasgow, United Kingdom
Dr Peter Meredith is a graduate of the Universities of Glasgow and Strathclyde and is currently Reader in Clinical Pharmacology in the Department of Medicine and Therapeutics of the University of Glasgow. He has held this appointment since 1997 having previously been a Lecturer and Senior Lecturer in the Department of Materia Medica of the University of Glasgow. He is based in the Gardiner Institute of the Western Infirmary, Glasgow, where most of his teaching commitments and research is undertaken. His principal research interests are in hypertension and various aspects of clinical cardiovascular pharmacology.
Over the last 10 years he has devoted considerable attention to the application of novel modelling techniques integrating pharmacokinetic and pharmacodynamic indices particularly in relation to the development of antihypertensive drugs and the "individualisation" of therapy in essential hypertensives. This has also incorporated assessment of the incidence and